Introduction
There are two major steps in cancer. Firstly, somatic cells lose growth controls and become sporadically transformed. The cause of transformation might be one or several of a variety of different environmental or genetic factors. However at this first stage there is only a minor risk for poor clinical prognosis. These primary tumours can then undergo a second step in which previously benign tumours are said to become malignant by their ability to form secondary tumours called metastases. Clinical prognosis for patients with metastasizing tumours is not optimistic. The aim of this review is to consider the role, if any, of methylCpG binding proteins in both stages of tumour progression.
Cancer: an epigenetic disease
Cancer is predominantly a genetic disease. Inactivation of tumour suppressor genes through changes in DNA sequence is a well-documented phenomenon in tumour progression (Knudson, 1997) . However the voices arguing that cancer can also be caused through transcriptional silencing by DNA methylation, making it also an epigenetic disease, have been growing stronger over the past decade (Jones and Laird, 1999) . By far the majority of reports linking DNA methylation and cancer focus on the observation that inappropriate transcriptional silencing of tumour suppressor genes is often accompanied by abnormal DNA methylation patterns in the regulatory sequences of these genes (Costello et al., 2000; Jones and Laird, 1999) . This abnormal methylation is usually found at CpG islands. CpG islands are short, C-and G-rich sequences associated with the 5' ends of genes which, despite being rich in the methylatable sequence CpG, are normally never methylated irrespective of the transcriptional status of the associated gene (Bird, 1987) . The observation that transcriptionally silent tumour suppressor genes are occasionally associated with abnormally methylated CpG islands in tumours begs the following question. Has inappropriate CpG island methylation caused the silencing of this gene (i.e. gene inactivation via epigenetic change), or has island methylation occurred subsequent to the gene being silenced by some other mechanism (i.e. gene inactivation via genetic change)?
Though this chicken-and-egg scenario has not yet been resolved, there is no question that the link between a cancerous cell and its DNA methylation profile is an important one. Once established, the methylation profile of tumour cells can reflect the transcriptional status of that cell. DNA methylation alone is not likely to be a primary event in gene inactivation (Buschhausen et al., 1987; Kass et al., 1997) . Rather, DNA methylation is thought to provide a long term and robust memory for 'locking in' a transcriptionally inactive state established by other mechanisms (Bird, 2002) . Once a given sequence becomes methylated, it then becomes a target for the binding of a methyl-CpG binding protein which, in turn, can induce changes in the surrounding chromatin to ensure that the repressed state is stably maintained Nan et al., 1998) , often lasting for the lifetime of the organism.
Methyl-CpG binding proteins are interpreters of the DNA methylation signal (Hendrich and Bird, 2000; Wade, 2001) . They are sequence-specific DNA binding proteins, but (in most cases; see below) their target sequence consists of only two base pairs: 5-methylcytosine followed by guanine (5mCpG), a sequence found throughout vertebrate genomes. Indeed, chromosomewide distribution has been demonstrated for two of these methyl-CpG binding proteins (Lewis et al., 1992; Ng et al., 2000) . At present there are five known methyl-CpG binding proteins in mammals (Cross et al., 1997; Hendrich and Bird, 1998; Nan et al., 1993; Prokhortchouk et al., 2001) (Figure 1 ). Four of these proteins, MeCP2, MBD1, MBD2, and MBD4, bind 5mCpG through a conserved protein motif called the methyl-CpG binding domain (MBD) (Nan et al., 1996) . Like these four proteins, the MBD3 protein contains this highly conserved MBD motif but, despite having over 70% amino acid similarity to the MBD2 protein, mammalian MBD3 has apparently lost the ability to specifically bind methylated DNA (Hendrich and Bird, 1998) . The fifth methyl-CpG binding protein, Kaiso, is different from the others in that it binds methylated DNA through a zinc finger motif (Prokhortchouk et al., 2001) (Figure 1) . Four of the methyl-CpG binding proteins, namely MBD1, MBD2, MeCP2 and Kaiso, have been shown to function as transcriptional repressors both in vitro and in cell culture assays; a large proportion of this repression being achieved through interaction with histone deacetylase complexes (Bird and Wolffe, 1999; Prokhortchouk et al., 2001) . The remaining methylCpG binding protein, MBD4, is not involved in transcriptional repression, but rather is implicated in DNA repair Hendrich et al., 1999) .
MBD4: maintaining methylation?
In addition to its role in transcriptional repression, 5-methylcytosine places a significant mutational load onto the genome. In humans, the mutation rate at 5-methylcytosine is 10 -50-fold higher than at other bases (Bulmer, 1986; Duncan and Miller, 1980; Sved and Bird, 1990) . Mutation at CpG is responsible for over one third of germline mutations associated with human genetic disease (Cooper and Krawczak, 1989) , as well as for many somatic mutations leading to cancer (Hollstein et al., 1994; Jones et al., 1992) . Whereas deamination of cytosine produces uracil which is efficiently removed from DNA (Lindahl et al., 1997) , deamination of 5-methylcytosine produces thymine, resulting in a T-G mismatch in the DNA. Two enzymes have been described that can remove thymidine from T-G mismatches in mammalian cells: TDG (Neddermann et al., 1996; Wiebauer and Jiricny, 1989) and MBD4 . Though MBD4 was first identified as a MBD-containing protein with a region of similarity to bacterial DNA repair enzymes (Hendrich and Bird, 1998) , it was independently identified through a two-hybrid assay using the mismatch repair protein MLH1 as bait . In this latter study, MBD4 was called MED1 for methyl-CpG binding endonuclease 1, though it has subsequently been demonstrated that this protein is actually a glycosylase and does not exhibit endonuclease activity Petronzelli et al., 2000) . Though the MBD of MBD4 can recognize symmetrically methylated CpG base pairs (Hendrich and Bird, 1998) , it much prefers to bind 5mCpG-TpG mismatches , which are the primary product of deamination at 5mCpG. Hence it has been proposed that the role of MBD4 is to minimize mutation at 5-methylcytosine .
If MBD4 does indeed play such a role in mammals, then one might expect loss of MBD4 to lead to a mutator phenotype that could promote tumorigenesis. If this hypothesis is correct, then biallelic loss or mutation of the MBD4 gene should be a characteristic of at least some tumour types. Two different groups set out to test this hypothesis by screening a number of different tumours for MBD4 mutations (Bader et al., 1999; Riccio et al., 1999) . Indeed, both groups identified insertions and deletions of a stretch of ten consecutive adenosines within the coding sequence of MBD4 in mismatch repair (MMR) defective tumours (Bader et al., 1999 (Bader et al., , 2000 Riccio et al., 1999) . Such mutations result in a frame-shift in the middle of the MBD4 coding sequence, preventing translation of the C-terminal glycosylase domain. A more surprising result was that mutation occurred on one allele only, and though loss of heterozygosity could be shown for four out of six samples in one study , no loss of heterozygosity could be demonstrated in the other study (Bader et al., 1999) . This is certainly not the normal pattern of mutation for tumour suppressor genes. It is possible that heterozygous mutation reduces functional MBD4 protein levels below some critical levels in these cells, or possibly that mutation results the production of a truncated MBD4 protein capable of binding to G-T mismatches, but unable to repair them.
Whatever the consequences of mutation for MBD4 function, the contribution of these observed mutations towards oncogenic transformation in MMR-defective tumours remains dubious. Indeed, Bader et al. (2000) provide evidence that MBD4 mutation occurred well after tumour formation in some samples. Further, mutation at the A 10 site in MBD4 was not found at a significantly increased frequency compared to mutation at other microsatellite sequences in MMR-defective intestinal carcinomas (Aaltonen et al., 1993; Bader et al., 1999; Ionov et al., 1993; Riccio et al., 1999; Thibodeau et al., 1993) . Thus these studies do not support a primary role for MBD4 in tumorigenesis, though its inactivation may be selectively advantageous in tumour progression.
MBD proteins: misled by methylation
The first molecular evidence for the importance of MBD proteins in control of gene transcription in vivo appeared from Alan Wolffe's lab in 2001 (Magdinier and Wolffe, 2001 ). These authors chose to investigate whether MBD2 and MeCP2 bind to the promoters of two important cell cycle regulatory genes, p14/ARF and p16/INK4A (Kamb et al., 1994) . These two genes occupy a single locus on human chromosome 9, but are transcribed from different CpG island promoters. Abnormal methylation of the p16 CpG island is a well documented early event in human cancers (Foster et al., 1998; Nuovo et al., 1999) . Methylation of the p14 CpG island occurs less frequently, though is observed in colon carcinomas (Esteller et al., 2000; Robertson and Jones, 1998) . Using chromatin immunoprecipitation assays (CHIP) in human colon cancer cell lines, Magdinier and Wolffe showed that MBD2 is physically associated with the CpG islands of p16 and p14 when these sequences are methylated. This finding implies that MBD2, and its associated repression complex MeCP1, contributes to the methylation-associated silencing of this locus in colon carcinoma cells. In contrast, these authors could find no evidence for the presence of the MeCP2 protein on either the p14 or p16 methylated CpG islands, though it was found to be associated with methylated alu sequence located downstream (Magdinier and Wolffe, 2001).
These in vivo observations fit well with the in vitroelucidated properties of these two proteins: while the DNA binding properties of the MeCP1 complex are consistent with preferential binding to DNA containing a high density of 5mCpG (such as would occur in a methylated CpG island) (Lewis et al., 1992) , the MeCP2 protein is more likely to bind to bulk chromatin . The reasons for such specificity are still unknown. The universality of this observed differential DNA binding by MBD2 and MeCP2 is cast into doubt by a more recent report in which MeCP2 was found physically associated with the methylated p14/p16 CpG island in one of the same colon cancer lines used in the above study, as well as in a bladder cancer line (Nguyen et al., 2001) . The reasons for this discrepancy are not immediately clear, though experimental technique may be a factor. Alternately, perhaps MeCP2 is either weakly or transiently associated with the methylated CpG island, whereas MeCP1 is more consistently bound. Further experiments will be required to clarify this issue.
Apparent discrepancies aside, what might we glean from these reports about the role of methyl-CpG binding proteins in cancer? It is gratifying, but not surprising, to find that proteins long suspected to be capable of binding to methylated CpG islands can, in some situations, bind methylated CpG islands. In binding to the methylated (and silent) p14 or p16 promoter regions, methyl-CpG binding proteins are just doing their job. Though they may be contributing to inappropriate silencing of tumour-suppressor genes, it is the presence of DNA methylation that lures them to this sequence, causing them to act where they should not. Yet the job of DNA methylation and methyl-CpG binding proteins in transcriptional silencing appears to be in maintaining the silent state, not establishing it (Buschhausen et al., 1987; Kass et al., 1997) . Hence we are back to the chicken-and-egg question: did DNA methylation alone cause this gene to be silenced, or was DNA methylation applied to a CpG island silenced by some other factor? The answer to this question is crucial to understanding the potential role of methylCpG binding proteins in contributing to the transformed phenotype. If the former case is true, then there may be some hope that the p14 and p16 genes could be reactivated if the activity of methyl-CpG binding proteins was abrogated. However if DNA methylation is merely reflecting the transcriptionally inactive status of these genes, then interfering with methyl-CpG binding proteins may do nothing towards reversing the primary event that resulted in silencing in the first place.
MBDs: more is better
In addition to DNA methylation being associated with a change in the transcriptional control of specific gene sequences, changes in total methylation levels can also have consequences for cancer susceptibility. Two different groups have found that a reduction in total DNA methylation levels in tumour susceptible mice actually reduced the number and growth rate of intestinal adenomas found in these mice (Cormier and Dove, 2000; Laird et al., 1995) . Consistent with decreased methylation correlating with protection from cancer, Saito et al. (2001) reported finding increased expression of DNA methyltransferases 1 and 3a in human hepatocellular carcinomas (HCCs), though no specific increase in DNA methylation was detected. This study also implicated decreased expression of MBD4 in malignant progression of HCCs, generally consistent with the idea that MBD4 can act as a tumour suppressor. These researchers also detected a slight reduction of MBD2 expression in HCCs, as well as a more marked reduction of MECP2 expression, while no significant alterations in the levels of MBD1 or MBD3 transcripts were observed. The same group earlier reported reduced mRNA expression of MBD2 in human colorectal and stomach cancers (Kanai et al., 1999) . This earlier study found that the drop in MBD2 mRNA levels in these cancers was much more pronounced than those found in the case of HCCs. These authors conclude that overexpression of DNA methyltransferases and reduced expression of MBD4 and MECP2 may be associated with malignant progression of HCCs.
This kind of analysis was recently extended for MECP2 and MBD2 to include a variety of primary human tumours (Muller-Tidow et al., 2001) . Again, significantly reduced MBD2 and MECP2 expression was found in several different tumour types. Expression levels were measured using real-time PCR and, in some cases involving MeCP2, RT -PCR data was confirmed by Western blotting showing parallel decrease of protein levels. Reduction of MECP2 and MBD2 mRNA levels was associated with neither p53 mutational status nor the prognosis of the disease. In agreement with the authors of the previous studies, these authors conclude that a decrease in expression of both MECP2 and MBD2 might play a role in the development of solid human tumours.
Summarizing these expression studies we find that the most conclusive statement we can make about methyl-CpG binding proteins and cancer is that it does appear that levels of MBD2, MECP2 and MBD4 expression are decreased in some tumours. The level of decrease is both gene-and tumour type-dependent, but seems to be independent of prognosis or stage of tumour progression. Hence it may be that a decrease in DNA methylation-dependent transcriptional regulation could contribute to cellular transformation. Yet this conclusion is in contrast to both evidence correlating increased methyltransferase expression with cancer in humans (Saito et al., 2001) , and with evidence that decreased methylation levels actually protect mice from intestinal neoplasia (Cormier and Dove, 2000; Laird et al., 1995) . How can these two apparently contradictory findings help us in understanding the relationship between methyl-CpG binding proteins and cancer? Though the potential contribution of decreased MBD2 and MeCP2 expression levels to tumorigenesis remains tenuous (see below), the case for an involvement of MBD4 in cancer is supported by both sets of data.
One factor (among others; see Chan et al., 2001 ) which may contribute to the findings of the murine studies (Cormier and Dove, 2000; Laird et al., 1995) comes back to the mutational load 5-methylcytosine places on the genome. A general reduction in the amount of 5mCpG in the genomes of mice harbouring a mutation in one allele of the Apc tumour suppressor gene (Su et al., 1992) presumably results in a decrease in the mutation frequency at CpG dinucleotides, thus reducing the probability of inactivating the second Apc allele or of inactivating other tumour suppressor genes. Similarly, reduced expression of MBD4 in HCCs may result in an increased mutation frequency at 5mCpG in these tumours, thereby contributing to tumour progression. Though currently highly speculative, this hypothesis is testable. Future genetic studies in mice can be used to definitively address the effects of Mbd4 gene inactivation in cancer.
Despite the observations that MBD2 and MECP2 transcript levels can be decreased in some tumours (Muller-Tidow et al., 2001; Saito et al., 2001) , there are good genetic data indicating that these genes do not function as tumour suppressor genes in the classical sense. This evidence comes from the finding that mutations in the X-linked MECP2 gene in humans cause Rett Syndrome (Amir et al., 1999) . Rett Syndrome is a neurodevelopmental disorder, affecting one in 10 000 female births (Kerr et al., 2001; Kerr and Stephenson, 1985) . Rett Syndrome patients are almost exclusively girls who are heterozygous for MECP2 mutation and, due to random X chromosome inactivation, are mosaic for cells expressing only the normal MECP2 allele and cells expressing only the mutant allele. Both point mutations and truncating mutations exist in Rett Syndrome patients which are very likely to result in completely non-functional MECP2 alleles (http://www.ed.ac.uk/ *skirmis/). Despite having on average half of their cells completely lacking any functional MeCP2 protein, there is no evidence that Rett patients are predisposed to cancer. Moreover, while targeted disruption of Mecp2 in mice produces Rett-like phenotypes (Chen et al., 2001; Guy et al., 2001) , there is no evidence that it leads to an increased incidence of tumours (J Guy, B Hendrich and A Bird, unpublished observations) . Similarly, there is no evidence for increased tumorigenesis in mice lacking the Mbd2 gene , or even in mice lacking both Mbd2 and Mecp2 .
These genetic experiments clearly show that reduction in the level of Mbd2 and MeCP2/Mecp2 gene expression is not sufficient to cause cellular transformation in mice or humans (in the case of MeCP2). So how do we explain the reduced transcript levels found in a number of different human tumour types? It is possible that this decrease in transcript level is somehow a consequence of cellular transformation, rather than a contributing factor. It is also possible, however, that reduction of MBD2 and MECP2 transcript levels might increase the probability that a cell having undergone the first few steps of oncogenic transformation will become fully cancerous. This intriguing possibility can be tested experimentally by reducing Mbd2 and/or Mecp2 transcript levels in certain cancer-prone mouse strains and determining the effects, if any, upon tumour formation.
Kaiso: a cytoplasmic-nuclear link
The most recently identified methyl-CpG binding protein, Kaiso, is different from the others in two major ways (Figure 1) . Firstly, it requires at least two symmetrically methylated CpG dinucleotides in its recognition sequence, preferably within the sequence 5'-5mCpGp5mCpG-3' (Prokhortchouk et al., 2001) . Secondly, Kaiso uses a zinc finger motif, rather than anything resembling a MBD, to specifically recognize methylated DNA (Prokhortchouk et al., 2001) . Like MBD1, 2 and MeCP2, Kaiso behaves as a methylation-dependent transcriptional repressor in transient transfection assays (Prokhortchouk et al., 2001) . Kaiso was originally identified due to its ability to associate with p120 catenin (Daniel and Reynolds, 1999) , a member of a subfamily of armadillo-domain proteins found at cell -cell junctions (Anastasiadis and Reynolds, 2000) . Despite its normal cytoplasmic localization, nuclear p120 has recently been observed in some cells, particularly metastatic cells that have lost E-cadherin expression (van Hengel et al., 1999) . Thus the identification of Kaiso as a p120-binding partner provides a molecular link between a methyl-CpG binding protein and a molecule strongly implicated in cancer. Though, like the other methyl-CpG binding proteins that have been shown to be capable of binding to methylated CpG islands in vitro (Prokhortchouk et al., 2001) , the actual in vivo targets for Kaiso remain to be identified. Nonetheless, through its interaction with p120 catenin, Kaiso is potentially a molecular link between cytoplasmic signalling and the interpretation of DNA methylation patterns. Given this tantalising connection it will be of particular interest to determine whether Kaiso plays any role in human cancers, as well as to determine its in vivo function in mammalian development.
Conclusions
In this review we have explored the existing data linking the five known methyl-CpG binding proteins, MeCP2, MBD1, MBD2, MBD4 and Kaiso, to cancer, i.e. from the basis of their potential to be prognostic markers for tumour progression or potential targets for therapeutic intervention. Though the limited pool of clinical and experimental data do not support a primary role for methyl-CpG binding proteins in tumorigenesis, they do offer a suggestion that reduced levels of MBD2, MeCP2 and MBD4 might be involved in tumour progression. Given that DNA methylation is usually associated with inappropriate silencing of genes in cancer, the contribution that a decrease in the levels of the methyl-CpG binding transcriptional repressors MBD2 and MeCP2 might make to tumorigenesis is not obvious. In contrast, the observation that expression of the 5mCpG-TpG binding G/T mismatch glycosylase MBD4 is decreased in some cancers is, though not compelling, certainly tantalising. In contrast, these studies provide no evidence that another methyl-CpG binding protein, MBD1, plays any role in cancer. Of all the methyl-CpG binding transcriptional repressors, it is the newest inductee into the methyl-CpG binding protein family, Kaiso, that has the best cancer credentials. Clearly the exact relationship between the methyl-CpG-dependent transcriptional repression activity of Kaiso and the normally cytoplasmic p120 catenin needs to be investigated, and any effects on cell growth or transformation explored fully. The overall picture of the relationship between methyl-CpG binding proteins and cancer is only just beginning to emerge, and we anticipate that this picture will become increasingly clear as new results are published. Although we can not say how this picture will look when it's all said and done, it's guaranteed to be interesting.
